Cargando…
Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer
Despite the confirmed anti-cancer effects of T-cell immune checkpoint inhibitors, in colorectal cancer (CRC) they are only effective in a small subset of patients with microsatellite-unstable tumors. Thus, therapeutics targeting other types of CRCs or tumors refractory to T-cell checkpoint inhibitor...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7975978/ https://www.ncbi.nlm.nih.gov/pubmed/33799989 http://dx.doi.org/10.3390/ijms22052690 |
_version_ | 1783667006606671872 |
---|---|
author | Sugimura-Nagata, Akane Koshino, Akira Inoue, Satoshi Matsuo-Nagano, Aya Komura, Masayuki Riku, Miho Ito, Hideaki Inoko, Akihito Murakami, Hideki Ebi, Masahide Ogasawara, Naotaka Tsuzuki, Toyonori Takahashi, Satoru Kasugai, Kunio Kasai, Kenji Inaguma, Shingo |
author_facet | Sugimura-Nagata, Akane Koshino, Akira Inoue, Satoshi Matsuo-Nagano, Aya Komura, Masayuki Riku, Miho Ito, Hideaki Inoko, Akihito Murakami, Hideki Ebi, Masahide Ogasawara, Naotaka Tsuzuki, Toyonori Takahashi, Satoru Kasugai, Kunio Kasai, Kenji Inaguma, Shingo |
author_sort | Sugimura-Nagata, Akane |
collection | PubMed |
description | Despite the confirmed anti-cancer effects of T-cell immune checkpoint inhibitors, in colorectal cancer (CRC) they are only effective in a small subset of patients with microsatellite-unstable tumors. Thus, therapeutics targeting other types of CRCs or tumors refractory to T-cell checkpoint inhibitors are desired. The binding of aberrantly expressed CD47 on tumor cells to signal regulatory protein-alpha (SIRPA) on macrophages allows tumor cells to evade immune destruction. Based on these observations, drugs targeting the macrophage checkpoint have been developed with the expectation of anti-cancer effects against T-cell immune checkpoint inhibitor-refractory tumors. In the present study, 269 primary CRCs were evaluated immunohistochemically for CD47, SIRPA, CD68, and CD163 expression to assess their predictive utility and the applicability of CD47–SIRPA axis-modulating drugs. Thirty-five percent of the lesions (95/269) displayed CD47 expression on the cytomembrane of CRC cells. CRCs contained various numbers of tumor-associated immune cells (TAIs) with SIRPA, CD68, or CD163 expression. The log-rank test revealed that patients with CD47-positive CRCs had significantly worse survival than CD47-negative patients. Multivariate Cox hazards regression analysis identified tubular-forming histology (hazard ratio (R) = 0.23), age < 70 years (HR = 0.48), and high SIRPA-positive TAI counts (HR = 0.55) as potential favorable factors. High tumor CD47 expression (HR = 1.75), lymph node metastasis (HR = 2.26), and peritoneal metastasis (HR = 5.80) were cited as potential independent risk factors. Based on our observations, CD47–SIRPA pathway-modulating therapies may be effective in patients with CRC. |
format | Online Article Text |
id | pubmed-7975978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79759782021-03-20 Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer Sugimura-Nagata, Akane Koshino, Akira Inoue, Satoshi Matsuo-Nagano, Aya Komura, Masayuki Riku, Miho Ito, Hideaki Inoko, Akihito Murakami, Hideki Ebi, Masahide Ogasawara, Naotaka Tsuzuki, Toyonori Takahashi, Satoru Kasugai, Kunio Kasai, Kenji Inaguma, Shingo Int J Mol Sci Article Despite the confirmed anti-cancer effects of T-cell immune checkpoint inhibitors, in colorectal cancer (CRC) they are only effective in a small subset of patients with microsatellite-unstable tumors. Thus, therapeutics targeting other types of CRCs or tumors refractory to T-cell checkpoint inhibitors are desired. The binding of aberrantly expressed CD47 on tumor cells to signal regulatory protein-alpha (SIRPA) on macrophages allows tumor cells to evade immune destruction. Based on these observations, drugs targeting the macrophage checkpoint have been developed with the expectation of anti-cancer effects against T-cell immune checkpoint inhibitor-refractory tumors. In the present study, 269 primary CRCs were evaluated immunohistochemically for CD47, SIRPA, CD68, and CD163 expression to assess their predictive utility and the applicability of CD47–SIRPA axis-modulating drugs. Thirty-five percent of the lesions (95/269) displayed CD47 expression on the cytomembrane of CRC cells. CRCs contained various numbers of tumor-associated immune cells (TAIs) with SIRPA, CD68, or CD163 expression. The log-rank test revealed that patients with CD47-positive CRCs had significantly worse survival than CD47-negative patients. Multivariate Cox hazards regression analysis identified tubular-forming histology (hazard ratio (R) = 0.23), age < 70 years (HR = 0.48), and high SIRPA-positive TAI counts (HR = 0.55) as potential favorable factors. High tumor CD47 expression (HR = 1.75), lymph node metastasis (HR = 2.26), and peritoneal metastasis (HR = 5.80) were cited as potential independent risk factors. Based on our observations, CD47–SIRPA pathway-modulating therapies may be effective in patients with CRC. MDPI 2021-03-07 /pmc/articles/PMC7975978/ /pubmed/33799989 http://dx.doi.org/10.3390/ijms22052690 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Sugimura-Nagata, Akane Koshino, Akira Inoue, Satoshi Matsuo-Nagano, Aya Komura, Masayuki Riku, Miho Ito, Hideaki Inoko, Akihito Murakami, Hideki Ebi, Masahide Ogasawara, Naotaka Tsuzuki, Toyonori Takahashi, Satoru Kasugai, Kunio Kasai, Kenji Inaguma, Shingo Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer |
title | Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer |
title_full | Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer |
title_fullStr | Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer |
title_full_unstemmed | Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer |
title_short | Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer |
title_sort | expression and prognostic significance of cd47–sirpa macrophage checkpoint molecules in colorectal cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7975978/ https://www.ncbi.nlm.nih.gov/pubmed/33799989 http://dx.doi.org/10.3390/ijms22052690 |
work_keys_str_mv | AT sugimuranagataakane expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT koshinoakira expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT inouesatoshi expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT matsuonaganoaya expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT komuramasayuki expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT rikumiho expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT itohideaki expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT inokoakihito expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT murakamihideki expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT ebimasahide expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT ogasawaranaotaka expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT tsuzukitoyonori expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT takahashisatoru expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT kasugaikunio expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT kasaikenji expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer AT inagumashingo expressionandprognosticsignificanceofcd47sirpamacrophagecheckpointmoleculesincolorectalcancer |